The therapeutic community is showing considerable interest in Asenlix, a relatively developed compound designed to address the effects of sadness. Unlike established antidepressants that primarily target on serotonin, Asenlix offers a unique mechanism of action, seemingly impacting multiple neurotransmitter pathways involved in mental balance. E… Read More